{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:53:23Z","timestamp":1793811203282,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03038-x","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:17:28Z","timestamp":1734333448000},"page":"863-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Qualitative Assessment of Health-Related Quality of Life Impacts Associated with Sickle Cell Disease in the United States and United Kingdom"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-9863","authenticated-orcid":false,"given":"Jennifer","family":"Drahos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Boateng-Kuffour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Pakbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"3038_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263\u201392. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-012838.","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"3038_CR2","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","volume":"10","author":"AM Thomson","year":"2023","unstructured":"Thomson AM, McHugh TA, Oron AP, Teply C, Lonberg N, Tella VV, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the global burden of disease study 2021. Lancet Haematol. 2023;10(8):e585\u201399. https:\/\/doi.org\/10.1016\/S2352-3026(23)00118-7.","journal-title":"Lancet Haematol"},{"issue":"4 Suppl","key":"3038_CR3","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","volume":"38","author":"KL Hassell","year":"2010","unstructured":"Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512\u201321. https:\/\/doi.org\/10.1016\/j.amepre.2009.12.022.","journal-title":"Am J Prev Med"},{"issue":"1 Suppl 1","key":"3038_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amepre.2015.11.002","volume":"51","author":"KL Hassell","year":"2016","unstructured":"Hassell KL. Sickle cell disease: a continued call to action. Am J Prev Med. 2016;51(1 Suppl 1):S1-2. https:\/\/doi.org\/10.1016\/j.amepre.2015.11.002.","journal-title":"Am J Prev Med"},{"issue":"3","key":"3038_CR5","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1093\/pubmed\/fdx172","volume":"40","author":"E Dormandy","year":"2018","unstructured":"Dormandy E, James J, Inusa B, Rees D. How many people have sickle cell disease in the UK? J Public Health (Oxf). 2018;40(3):e291\u20135. https:\/\/doi.org\/10.1093\/pubmed\/fdx172.","journal-title":"J Public Health (Oxf)"},{"issue":"16","key":"3038_CR6","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","volume":"376","author":"FB Piel","year":"2017","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561\u201373. https:\/\/doi.org\/10.1056\/NEJMra1510865.","journal-title":"N Engl J Med"},{"key":"3038_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100982","volume":"56","author":"M Stokoe","year":"2022","unstructured":"Stokoe M, Zwicker HM, Forbes C, Abu-Saris N, Fay-McClymont TB, Desire N, et al. Health related quality of life in children with sickle cell disease: a systematic review and meta-analysis. Blood Rev. 2022;56: 100982. https:\/\/doi.org\/10.1016\/j.blre.2022.100982.","journal-title":"Blood Rev"},{"issue":"4","key":"3038_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.pedhc.2009.12.006","volume":"25","author":"JC Dale","year":"2011","unstructured":"Dale JC, Cochran CJ, Roy L, Jernigan E, Buchanan GR. Health-related quality of life in children and adolescents with sickle cell disease. J Pediatr Health Care. 2011;25(4):208\u201315. https:\/\/doi.org\/10.1016\/j.pedhc.2009.12.006.","journal-title":"J Pediatr Health Care"},{"issue":"2","key":"3038_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ajh.21905","volume":"86","author":"C Dampier","year":"2011","unstructured":"Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203\u20135. https:\/\/doi.org\/10.1002\/ajh.21905.","journal-title":"Am J Hematol"},{"key":"3038_CR10","doi-asserted-by":"crossref","unstructured":"Drahos J, Boateng-Kuffour A, Calvert M, Valentine A, Mason A, Li N, et al. Sustained humanistic burden and work impact in adults with sickle cell disease with recurrent vaso-occlusive crises: results from a global longitudinal survey. ISPOR 2023, Boston, MA, USA. PCR85 ed2023.","DOI":"10.1016\/j.jval.2023.03.1863"},{"issue":"6","key":"3038_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11136-019-02412-5","volume":"29","author":"AA Rizio","year":"2020","unstructured":"Rizio AA, Bhor M, Lin X, McCausland KL, White MK, Paulose J, et al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020;29(6):1533\u201347. https:\/\/doi.org\/10.1007\/s11136-019-02412-5.","journal-title":"Qual Life Res"},{"issue":"8","key":"3038_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29685","volume":"69","author":"KL Moody","year":"2022","unstructured":"Moody KL. Healthcare utilization and the quality of life of children and adolescents with sickle cell disease. Pediatr Blood Cancer. 2022;69(8): e29685. https:\/\/doi.org\/10.1002\/pbc.29685.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3038_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/bloodadvances.2019000128","volume":"4","author":"KS Esham","year":"2020","unstructured":"Esham KS, Rodday AM, Smith HP, Noubary F, Weidner RA, Buchsbaum RJ, et al. Assessment of health-related quality of life among adults hospitalized with sickle cell disease vaso-occlusive crisis. Blood Adv. 2020;4(1):19\u201327. https:\/\/doi.org\/10.1182\/bloodadvances.2019000128.","journal-title":"Blood Adv"},{"issue":"3","key":"3038_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jpainsymman.2022.05.003","volume":"64","author":"KL Moody","year":"2022","unstructured":"Moody KL. Association of sickle cell pain & symptoms on health-related quality of life among pediatric patients. J Pain Symptom Manag. 2022;64(3):304\u20139. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.05.003.","journal-title":"J Pain Symptom Manag"},{"issue":"8","key":"3038_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/MPH.0000000000000431","volume":"37","author":"LM Anderson","year":"2015","unstructured":"Anderson LM, Allen TM, Thornburg CD, Bonner MJ. Fatigue in children with sickle cell disease: association with neurocognitive and social-emotional functioning and quality of life. J Pediatr Hematol Oncol. 2015;37(8):584\u20139. https:\/\/doi.org\/10.1097\/MPH.0000000000000431.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"3038_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ajh.26063","volume":"96","author":"I Osunkwo","year":"2021","unstructured":"Osunkwo I, Andemariam B, Minniti CP, Inusa BPD, El Rassi F, Francis-Gibson B, et al. Impact of sickle cell disease on patients\u2019 daily lives, symptoms reported, and disease management strategies: results from the international sickle cell world assessment survey (SWAY). Am J Hematol. 2021;96(4):404\u201317. https:\/\/doi.org\/10.1002\/ajh.26063.","journal-title":"Am J Hematol"},{"key":"3038_CR17","unstructured":"Sick Cells. 2023. https:\/\/sickcells.org\/. Accessed Nov 2023."},{"key":"3038_CR18","unstructured":"Sickle Cell Care Manchester. 2023. https:\/\/sicklecellcaremanchester.co.uk\/. Accessed Nov 2023."},{"key":"3038_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117. https:\/\/doi.org\/10.1186\/1471-2288-13-117.","journal-title":"BMC Med Res Methodol"},{"key":"3038_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). The guidelines manual: appendices B\u2013I. 2012. https:\/\/www.nice.org.uk\/process\/pmg6\/resources\/the-guidelines-manual-appendices-bi-pdf-3304416006853. Accessed Nov 2023."},{"issue":"6","key":"3038_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042.","journal-title":"Int J Qual Health Care"},{"key":"3038_CR22","unstructured":"The Association of the British Pharmaceutical Industry. Code of Practice for the Pharmaceutical Industry 2021. 2021. https:\/\/www.abpi.org.uk\/publications\/code-of-practice-for-the-pharmaceutical-industry-2021\/. Accessed Nov 2023."},{"key":"3038_CR23","unstructured":"British Healthcare Business Intelligence Association. Legal and Ethical Guidelines for Healthcare Market Research. Your essential guide. 2023. https:\/\/www.bhbia.org.uk\/guidelines-and-legislation\/legal-and-ethical-guidelines. Accessed Nov 2023."},{"key":"3038_CR24","unstructured":"European Pharmaceutical Market Research Association. Code of Conduct. 2022. https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf. Accessed Nov 2023."},{"issue":"2","key":"3038_CR25","first-page":"e633","volume":"10","author":"FB Piel","year":"2023","unstructured":"Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: a lancet haematology commission. Hematology. 2023;10(2):e633\u201386.","journal-title":"Hematology"},{"issue":"2","key":"3038_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30089","volume":"70","author":"H Khan","year":"2023","unstructured":"Khan H, Krull M, Hankins JS, Wang WC, Porter JS. Sickle cell disease and social determinants of health: a scoping review. Pediatr Blood Cancer. 2023;70(2): e30089. https:\/\/doi.org\/10.1002\/pbc.30089.","journal-title":"Pediatr Blood Cancer"},{"key":"3038_CR27","unstructured":"Omoigui S. How to manage an acute pain crisis in sickle cell disease: practical recommendations. Pract Pain Manag. 2021;21(3)."},{"issue":"1","key":"3038_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ajh.23341","volume":"88","author":"AM Brandow","year":"2013","unstructured":"Brandow AM, Stucky CL, Hillery CA, Hoffmann RG, Panepinto JA. Patients with sickle cell disease have increased sensitivity to cold and heat. Am J Hematol. 2013;88(1):37\u201343. https:\/\/doi.org\/10.1002\/ajh.23341.","journal-title":"Am J Hematol"},{"issue":"10","key":"3038_CR29","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/children9101478","volume":"9","author":"ME Guerzoni","year":"2022","unstructured":"Guerzoni ME, Marchesi S, Palazzi G, Lodi M, Pinelli M, Venturelli D, et al. Environmental factors in Northern Italy and sickle cell disease acute complications: a multicentric study. Children (Basel). 2022;9(10):1478. https:\/\/doi.org\/10.3390\/children9101478.","journal-title":"Children (Basel)"},{"issue":"4","key":"3038_CR30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3324\/haematol.2016.154245","volume":"102","author":"FB Piel","year":"2017","unstructured":"Piel FB, Tewari S, Brousse V, Analitis A, Font A, Menzel S, et al. Associations between environmental factors and hospital admissions for sickle cell disease. Haematologica. 2017;102(4):666\u201375. https:\/\/doi.org\/10.3324\/haematol.2016.154245.","journal-title":"Haematologica"},{"issue":"9","key":"3038_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3324\/haematol.2014.120030","volume":"100","author":"S Tewari","year":"2015","unstructured":"Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100(9):1108\u201316. https:\/\/doi.org\/10.3324\/haematol.2014.120030.","journal-title":"Haematologica"},{"key":"3038_CR32","doi-asserted-by":"publisher","first-page":"8296139","DOI":"10.1155\/2018\/8296139","volume":"2018","author":"SM Badawy","year":"2018","unstructured":"Badawy SM, Barrera L, Cai S, Thompson AA. Association between participants\u2019 characteristics, patient-reported outcomes, and clinical outcomes in youth with sickle cell disease. Biomed Res Int. 2018;2018:8296139. https:\/\/doi.org\/10.1155\/2018\/8296139.","journal-title":"Biomed Res Int"},{"issue":"10","key":"3038_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28492","volume":"67","author":"LE Crosby","year":"2020","unstructured":"Crosby LE, Hood A, Kidwell K, Nwankwo C, Peugh J, Strong H, et al. Improving self-management in adolescents with sickle cell disease. Pediatr Blood Cancer. 2020;67(10): e28492. https:\/\/doi.org\/10.1002\/pbc.28492.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"3038_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1348\/135910710X529278","volume":"16","author":"H Caird","year":"2011","unstructured":"Caird H, Camic PM, Thomas V. The lives of adults over 30 living with sickle cell disorder. Br J Health Psychol. 2011;16(3):542\u201358. https:\/\/doi.org\/10.1348\/135910710X529278.","journal-title":"Br J Health Psychol"},{"issue":"8","key":"3038_CR35","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/jpepsy\/jsab034","volume":"46","author":"LA Wright","year":"2021","unstructured":"Wright LA, Cohen LL, Gise J, Shih S, Sil S, Carter S. Pain and QOL in pediatric sickle cell disease: buffering by resilience processes. J Pediatr Psychol. 2021;46(8):1015\u201324. https:\/\/doi.org\/10.1093\/jpepsy\/jsab034.","journal-title":"J Pediatr Psychol"},{"issue":"5","key":"3038_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14070","volume":"6","author":"KM Harris","year":"2023","unstructured":"Harris KM, Preiss L, Varughese T, Bauer A, Calhoun CL, Treadwell M, et al. Examining mental health, education, employment, and pain in sickle cell disease. JAMA Netw Open. 2023;6(5): e2314070. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14070.","journal-title":"JAMA Netw Open"},{"issue":"23","key":"3038_CR37","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1182\/bloodadvances.2017006940","volume":"1","author":"SS Adam","year":"2017","unstructured":"Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Adv. 2017;1(23):1983\u201392. https:\/\/doi.org\/10.1182\/bloodadvances.2017006940.","journal-title":"Blood Adv"},{"issue":"16","key":"3038_CR38","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/bloodadvances.2020001743","volume":"4","author":"J Kanter","year":"2020","unstructured":"Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, et al. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020;4(16):3804\u201313. https:\/\/doi.org\/10.1182\/bloodadvances.2020001743.","journal-title":"Blood Adv"},{"issue":"11","key":"3038_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050880","volume":"11","author":"MP Smeltzer","year":"2021","unstructured":"Smeltzer MP, Howell KE, Treadwell M, Preiss L, King AA, Glassberg JA, et al. Identifying barriers to evidence-based care for sickle cell disease: results from the sickle cell disease Implementation consortium cross-sectional survey of healthcare providers in the USA. BMJ Open. 2021;11(11): e050880. https:\/\/doi.org\/10.1136\/bmjopen-2021-050880.","journal-title":"BMJ Open"},{"issue":"3","key":"3038_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265342","volume":"17","author":"S Phillips","year":"2022","unstructured":"Phillips S, Chen Y, Masese R, Noisette L, Jordan K, Jacobs S, et al. Perspectives of individuals with sickle cell disease on barriers to care. PLoS ONE. 2022;17(3): e0265342. https:\/\/doi.org\/10.1371\/journal.pone.0265342.","journal-title":"PLoS ONE"},{"key":"3038_CR41","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1056\/NEJMp2022125","volume":"383","author":"A Powers-Hays","year":"2020","unstructured":"Powers-Hays A, McGann P. When actions speak louder than words \u2014 racism and sickle cell disease. N Engl J Med. 2020;383:1902\u20133. https:\/\/doi.org\/10.1056\/NEJMp2022125.","journal-title":"N Engl J Med"},{"issue":"1","key":"3038_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/27527530221090179","volume":"40","author":"J Reich","year":"2023","unstructured":"Reich J, Cantrell MA, Smeltzer SC. An integrative review: the evolution of provider knowledge, attitudes, perceptions and perceived barriers to caring for patients with sickle cell disease 1970-now. J Pediatr Hematol Oncol Nurs. 2023;40(1):43\u201364. https:\/\/doi.org\/10.1177\/27527530221090179.","journal-title":"J Pediatr Hematol Oncol Nurs"},{"key":"3038_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PPA.S377924","volume":"17","author":"N Durgam","year":"2023","unstructured":"Durgam N, Brion T, Lewis HB, Tinga B, Sanon W, Lundie M, et al. Patient and caregiver perspectives on care-seeking during a vaso-occlusive crisis in sickle cell disease: results from qualitative interviews in Canada. Patient Prefer Adherence. 2023;17:41\u20139. https:\/\/doi.org\/10.2147\/PPA.S377924.","journal-title":"Patient Prefer Adherence"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03038-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03038-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:51Z","timestamp":1738407231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03038-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3038"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03038-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"1 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jennifer Drahos, Adriana A. Boateng-Kuffour, and Nanxin Li are employees of Vertex Pharmaceuticals Incorporated and may hold stock or stock options in the company. Melanie Calvert is Director of Birmingham Health Partners Centre for Regulatory Science and Innovation and Centre for Patient Reported Outcomes Research and a National Institute for Health and Care Research (NIHR) senior investigator; has received funding from Anthony Nolan, European Regional Development Fund-Demand Hub and Health Data Research UK, Gilead, GlaxoSmithKline, Janssen, Macmillan Cancer Support, Merck, NIHR, NIHR ARC WM, NIHR Birmingham BRC, NIHR BTRU Precision and Cellular Therapeutics, UCB Pharma, UKRI, and UK SPINE; and has received consultancy fees from Aparito, Astellas, CIS Oncology, Daiichi Sankyo, Gilead, Glaukos, GlaxoSmithKline, Halfloop, Merck, Patient-Centered Outcomes Research Institute, Pfizer, Takeda, and Vertex Pharmaceuticals Incorporated. Ashley Valentine has received consulting fees for Atlas Clarity Consulting Firm and Vertex Pharmaceuticals Incorporated; acted as Board of Director for IVI; and acted as an advisory board member for PCORI. Anthony Mason has received consulting fees for Vertex Pharmaceuticals Incorporated. Zahra Pakbaz has received research grants from Amgen, Forma Therapeutics, Global Blood Therapeutics, Novartis, NovoNordisk, and Pfizer; received consulting fees from Agio, Amgen, Dova, Global Blood Therapeutics, Guide point, Novartis, Sanofi, Sobi, and Vertex Pharmaceuticals Incorporated; received honoraria from Cayeene Wellness Center and Child Foundation, Dova, and Global Blood Therapeutics Inc; served as an advisory board or committee member for Alexion, Sanofi, and Sobi; and acted as a CME course director for the Cayenne Wellness Center and Child Foundation and planning committee member for their annual education symposium. Farrukh Shah has received research grants from IQVIA, Novartis Pharma AG, and Vertex Pharmaceuticals Incorporated; received honoraria from Biologix FZ co, Bristol Myers Squibb, Chiesi Ltd, and Novartis Pharma AG; served as an advisory board or committee member for Agios, bluebird bio, Bristol Myers Squibb, Silence Therapeutics Plc, and Vertex Pharmaceuticals Incorporated; and acted as Chair for the UK Forum on Haemoglobin Disorders. Antony P. Martin is a partner of QC Medica who was funded by Vertex Pharmaceuticals Incorporated to perform this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments, as well as with the Association of the British Pharmaceutical Industry, British Healthcare Business Intelligence Association, and European Pharmaceutical Market Research Association codes of conduct [\u2013]. All participants provided informed consent for participation and publication of the results before participating in the study. Participant eligibility was determined using the study\u2019s inclusion\/exclusion criteria, fielded through an eligibility screening questionnaire. The WIRB-Copernicus Group\u00ae Institutional Review Board reviewed the study and granted exemption based on 45 CFR \u00a7 46.104(d)(2).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}